Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Sells 36,825 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXGet Rating) CEO Christopher Gibson sold 36,825 shares of the stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $9.49, for a total transaction of $349,469.25. Following the completion of the transaction, the chief executive officer now directly owns 541,829 shares of the company’s stock, valued at $5,141,957.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Christopher Gibson also recently made the following trade(s):

  • On Thursday, July 7th, Christopher Gibson sold 37,114 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.05, for a total transaction of $335,881.70.
  • On Thursday, June 2nd, Christopher Gibson sold 39,690 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $6.09, for a total transaction of $241,712.10.

Recursion Pharmaceuticals Trading Up 3.2 %

Shares of RXRX stock traded up $0.31 during trading hours on Friday, reaching $9.91. 640,317 shares of the stock were exchanged, compared to its average volume of 1,086,274. Recursion Pharmaceuticals, Inc. has a 12-month low of $4.92 and a 12-month high of $31.43. The company’s 50-day moving average price is $7.92 and its 200-day moving average price is $8.10. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of -7.43 and a beta of -0.48.

Recursion Pharmaceuticals (NASDAQ:RXRXGet Rating) last posted its quarterly earnings results on Tuesday, May 10th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of $0.51 by ($0.84). Recursion Pharmaceuticals had a negative net margin of 1,635.19% and a negative return on equity of 37.18%. The business had revenue of $5.33 million during the quarter, compared to the consensus estimate of $152.90 million. On average, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.39 EPS for the current year.

Wall Street Analyst Weigh In

RXRX has been the topic of several research reports. The Goldman Sachs Group dropped their target price on shares of Recursion Pharmaceuticals from $9.00 to $7.00 and set a “neutral” rating on the stock in a report on Tuesday, May 24th. Bank of America cut shares of Recursion Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $10.00 price target on the stock. in a research note on Monday, April 18th.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Daiwa Securities Group Inc. purchased a new stake in Recursion Pharmaceuticals during the fourth quarter valued at approximately $88,000. MV Management XI L.L.C. purchased a new stake in Recursion Pharmaceuticals during the fourth quarter valued at approximately $33,779,000. Massachusetts Financial Services Co. MA raised its holdings in shares of Recursion Pharmaceuticals by 45.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,300,041 shares of the company’s stock worth $22,270,000 after buying an additional 404,181 shares during the last quarter. Spouting Rock Asset Management LLC raised its holdings in shares of Recursion Pharmaceuticals by 70.7% in the fourth quarter. Spouting Rock Asset Management LLC now owns 90,203 shares of the company’s stock worth $1,545,000 after buying an additional 37,352 shares during the last quarter. Finally, Virtus ETF Advisers LLC purchased a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth $151,000. Hedge funds and other institutional investors own 55.25% of the company’s stock.

Recursion Pharmaceuticals Company Profile

(Get Rating)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.

Featured Stories

Insider Buying and Selling by Quarter for Recursion Pharmaceuticals (NASDAQ:RXRX)

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.